AbCellera Biologics (ABCL) Retained Earnings (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Retained Earnings data on file, last reported at -$2.4 million in Q1 2026.

• Quarterly Retained Earnings rose 65.43% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (up 65.43% YoY) and the FY2025 annual result came in at -$29.5 million, down 573.41% from the prior year.
• Retained Earnings climbed to -$2.4 million in Q1 2026, from -$29.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $436.2 million in Q1 2022 to a low of -$29.5 million in Q4 2025.
• A 5-year average of $96.8 million and a median of -$1.5 million in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 596.79% — and 2023, when it surged 20214.09%.
• Tracing ABCL's Retained Earnings over 5 years: stood at -$1.4 million in 2022, then jumped by 20214.09% to $279.8 million in 2023, then sank by 101.56% to -$4.4 million in 2024, then slumped by 573.41% to -$29.5 million in 2025, then soared by 91.79% to -$2.4 million in 2026.
• The last three Retained Earnings figures came in at -$2.4 million (Q1 2026), -$29.5 million (Q4 2025), and -$20.5 million (Q3 2025), per Business Quant data.